Small-Molecule Cardiomyocyte Maturation for Congenital DCM

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Infantile dilated cardiomyopathy (iDCM) is a rare and challenging condition with significant morbidity and mortality, often requiring heart transplants due to genetic mutations affecting cardiomyocyte maturation and structure, particularly in genes related to sarcomere structure and mitochondria, with limited understanding of the centrosome's role in cardiac development.

Innovation Solution

Administration of Hippo pathway activators, such as C19, to induce cardiomyocyte maturation by promoting centrosome reduction and restoring normal microtubule organization, addressing the structural and functional defects in cardiomyocytes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If heart transplant is used to treat infantile dilated cardiomyopathy, then cardiac function is restored, but donor hearts are scarce and transplant burden is high

Engineering Contradiction:

Improvecardiac function restorationVSAvoiddonor availability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies self-service by enabling the patient's own cardiomyocytes to mature and restore cardiac function through Hippo pathway activation, eliminating the need for donor hearts. The small molecule compounds activate the Hippo pathway in the patient's existing cardiomyocytes, allowing them to autonomously undergo maturation and improve contractility without external intervention from donor organs.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent utilizes parameter changes by modifying the maturation state of cardiomyocytes through pharmacological intervention. The small molecule compounds change the biological parameters of cardiomyocyte development, transitioning them from an immature state to a mature state, thereby improving cardiac function without requiring organ replacement.

Inventive Principle:

Principle #35Parameter changes

2Stability of the object's composition

If conventional cardiomyocyte maturation is blocked, then cell cycle arrest occurs, but cardiac structure and function deteriorate

Engineering Contradiction:

Improvecardiomyocyte maturationVSAvoidcardiac function

Core Design Contradiction:

Stability of the object's compositionVSReliability

Solution Approach 1:

The patent implements feedback by using the Hippo pathway as a regulatory mechanism that senses and responds to cardiomyocyte maturation status. The pathway provides feedback control to ensure proper maturation progression, and the small molecule compounds enhance this feedback mechanism to overcome blocked maturation and restore cardiac function.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent applies parameter changes by pharmacologically activating the Hippo pathway to alter the maturation parameters of cardiomyocytes. This intervention changes the biological state from blocked maturation to active maturation progression, restoring both structure and function.

Inventive Principle:

Principle #35Parameter changes

3Manufacturing precision

If genetic mutations affect sarcomere structure and mitochondria, then cardiomyocyte maturation is impaired, but targeted therapy options are limited

Engineering Contradiction:

Improvesarcomere structureVSAvoidtherapy development

Core Design Contradiction:

Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent applies universality by identifying the Hippo pathway as a universal therapeutic target that can compensate for various genetic mutations affecting sarcomere structure and mitochondria. Rather than developing mutation-specific therapies, the pathway activator works across different genetic backgrounds to restore maturation, making the treatment broadly applicable to multiple forms of cardiomyopathy.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent uses the Hippo pathway as an intermediary mechanism between genetic defects and cardiac phenotypes. The pathway acts as a compensatory bridge that can be activated to overcome the negative effects of mutations, translating genetic vulnerabilities into treatable biological targets.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250268870A1Small molecule inducers of cardiomyocytes to improve cardiac structure and function

Publication Date: 2025.08.28 UNIV OF MARYLAND

AI summary

Here, we describe an infant with congenital dilated cardiomyopathy (cDCM) whose impaired cardiac function and disrupted sarcomere and mitochondria structures were modeled using induced pluripotent stem cells (iPSCs). The causal gene encodes the centrosomal protein rotatin (RTTN), representing the first time a centrosome defect has been found to cause nonsyndromic dilated cardiomyopathy (DCM) in humans. Genetic knockdowns in zebrafish and Drosophila confirmed an evolutionarily conserved requirement of RTTN for cardiac structure and function. The small molecule, C19, restored initiation of the perinuclear MTOC, and significantly improved the structure and function of cardiomyocytes. In summary, this study provides a new therapeutic strategy for infantile or congenital DCM.